GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hyperfine Inc (NAS:HYPR) » Definitions » ROE %

Hyperfine (Hyperfine) ROE % : -47.97% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Hyperfine ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Hyperfine's annualized net income for the quarter that ended in Dec. 2023 was $-42.74 Mil. Hyperfine's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $89.08 Mil. Therefore, Hyperfine's annualized ROE % for the quarter that ended in Dec. 2023 was -47.97%.

The historical rank and industry rank for Hyperfine's ROE % or its related term are showing as below:

HYPR' s ROE % Range Over the Past 10 Years
Min: -103.62   Med: -47.21   Max: -42.51
Current: -42.71

During the past 5 years, Hyperfine's highest ROE % was -42.51%. The lowest was -103.62%. And the median was -47.21%.

HYPR's ROE % is ranked worse than
74.91% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs HYPR: -42.71

Hyperfine ROE % Historical Data

The historical data trend for Hyperfine's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperfine ROE % Chart

Hyperfine Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -103.62 -47.21 -42.51

Hyperfine Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.38 -41.14 -39.39 -43.67 -47.97

Competitive Comparison of Hyperfine's ROE %

For the Medical Devices subindustry, Hyperfine's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyperfine's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hyperfine's ROE % distribution charts can be found below:

* The bar in red indicates where Hyperfine's ROE % falls into.



Hyperfine ROE % Calculation

Hyperfine's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-44.238/( (123.722+84.399)/ 2 )
=-44.238/104.0605
=-42.51 %

Hyperfine's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-42.736/( (93.767+84.399)/ 2 )
=-42.736/89.083
=-47.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Hyperfine  (NAS:HYPR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-42.736/89.083
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-42.736 / 10.744)*(10.744 / 98.6315)*(98.6315 / 89.083)
=Net Margin %*Asset Turnover*Equity Multiplier
=-397.77 %*0.1089*1.1072
=ROA %*Equity Multiplier
=-43.32 %*1.1072
=-47.97 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-42.736/89.083
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-42.736 / -42.736) * (-42.736 / -46.516) * (-46.516 / 10.744) * (10.744 / 98.6315) * (98.6315 / 89.083)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9187 * -432.95 % * 0.1089 * 1.1072
=-47.97 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Hyperfine ROE % Related Terms

Thank you for viewing the detailed overview of Hyperfine's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyperfine (Hyperfine) Business Description

Traded in Other Exchanges
N/A
Address
351 New Whitfield Street, Guilford, CT, USA, 06437
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. Legacy Hyperfine and Liminal represent two operating segments of the company. The company derives its sales from the following sources: 1) device sales which consist of sales of MRI devices and 2) service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Executives
Thomas Teisseyre officer: Chief Operating Officer C/O HYPERFINE, INC., 351 NEW WHITFIELD STREET, GUILFORD CT 06437
Khan Siddiqui officer: See Remarks 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Brett Hale officer: Chief Administrative Officer C/O HYPERFINE, INC., 351 NEW WHITFIELD STREET, GUILFORD CT 06437
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Jonathan M Rothberg director, 10 percent owner C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD ST., GUILFORD CT 06437
Alok Gupta officer: Chief Financial Officer 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Neela Paykel officer: Gen Counsel & Corp Secretary 530 OLD WHITFIELD STREET, GUILFORD CT 06437
David D Scott director, officer: President and CEO 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Ruth A Fattori director 1303 EAST ALGONQUIN ROAD, SCHAUMBURG IL 60196
Hc Sponsor Llc 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, 28TH FLOOR, NEW YORK NY 10001
Arthur Bruce Cohen 10 percent owner 12 SOUTH MAIN STREET, SUITE #203, NORWALK CT 06854
Healthcor Group, Llc 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
Scott A. White officer: Chief Commercial Officer 530 OLD WHITFIELD STREET, GUILFORD CT 06437